Endometriosis market set to reach $2.72 billion driven by new GnRH receptor agonists

New gonadotropin-releasing hormone (GnRH) receptor antagonists being introduced to the endometriosis market, will push the sector’s value up from $1.05 billion in 2020 to $2.72 billion in 2030 across the seven major markets (7MM: the USA, 5EU [France, Germany, Italy, Spain, and the UK], and Japan), according to data and analytics company GlobalData.

“Despite the availability of 17 marketed therapies from several different drug classes, the level of unmet need in the endometriosis market remains significant. The efficacy of many endometriosis therapies often diminishes over time, and women frequently experience side effects including menopausal-like symptoms and decreases in bone mineral density. As a result, compliance is affected and invasive surgical intervention is made, often repeatedly throughout the reproductive years,” noted GlobalData’s healthecare analyst Amy Murray.

The company’s latest report, ‘ Endometriosis Market Size and Trend Report, 2020-2030’, reveals that the market release of several GnRH antagonists including Myovant’s (NYSE: MYOV) relugolix combination tablet, sold under the brand names Myfembree and Ryeqo in the USA and 5EU, respectively, will be key drivers of growth in the endometriosis market. Kissei Pharmaceutical’s (TYO: 4547) GnRH antagonist, Yselty (linzagolix), will be another important driver of growth during the forecast period. This drug class is expected to represent 69.6% of the endometriosis market in 2030, equivalent to approximately $1.89 billion.